# PLACEHOLDER TRACKING
# S-1 text slots that need to be filled from SEC filings

## STATUS SUMMARY
- Total: 31
- Filled: 0
- Remaining: 31

## CHECKS 3, 4, 5 (17 slots) — Source: checks_3_4_5.md

| # | Company | Check | Placeholder Location | Filing URL | Status |
|---|---------|-------|---------------------|-----------|--------|
| 1 | Curanex Pharmaceuticals | 3 | Line 45 — S-1 text: "promising efficacy in animal models" + "superior anti-inflammatory" paragraphs | https://www.sec.gov/Archives/edgar/data/2025942/000149315224041335/forms-1.htm | PENDING |
| 2 | Virpax Pharmaceuticals | 3 | Line 106 — S-1 text: "pain control for up to 96 hours" + "comparable preclinical activity to morphine" paragraphs | https://www.sec.gov/Archives/edgar/data/1708331/000101376224002110/ea0209752-s1_virpaxphar.htm | PENDING |
| 3 | AARD (target S-1) | 3 | Line 237 — Preclinical passages with section headers and page numbers | — (target S-1 under review) | PENDING |
| 4 | Nuvalent (comparative) | 4 | Line 480 — S-1 text: "potential best-in-class" from pages 3, 118, 130 | https://www.sec.gov/Archives/edgar/data/1861560/000119312521209001/d174530ds1.htm | PENDING |
| 5 | Zenas BioPharma | 4 | Line 524 — S-1 text: "safer" and "more effective" re obexelimab | https://www.sec.gov/Archives/edgar/data/1953926/000110465924091950/tm2332800-11_s1.htm | PENDING |
| 6 | Khosla/Valo Health | 4 | Line 567 — S-4 text: comparison to S1P1R functional antagonists | https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001841873&type=S-4 | PENDING |
| 7 | AARD (target S-1) | 4 | Line 677 — Comparative "differentiated" passage with section and page | — (target S-1 under review) | PENDING |
| 8 | AVEO Pharmaceuticals (complaint) | 5 | Line 946 — Key complaint paragraphs: selective positive/negative FDA disclosure | https://www.sec.gov/divisions/enforce/claims/docs/aveo-complaint-090116.pdf | PENDING |
| 9 | AVEO Pharmaceuticals (litigation release) | 5 | Line 960 — Summary of charges, outcome, penalties | https://www.sec.gov/enforcement-litigation/distributions-harmed-investors/sec-v-aveo-pharmaceuticals-inc-et-al-case-no-16-cv-10607-d-mass | PENDING |
| 10 | Tongue v. Sanofi (case law) | 5 | Line 987 — Key holdings on duty to disclose negative FDA communications | https://www.stblaw.com/about-us/publications/view/2024/01/23/second-circuit-decides-two-matters-of-first-impression-concerning-challenged-statements-on-scientific-studies-and-data-interpretation | PENDING |
| 11 | Aerovate Therapeutics | 5 | Line 1008 — S-1 text: "FDA guidance supports NDA" + "efficient clinical development program" | https://www.sec.gov/Archives/edgar/data/1798749/000110465921078871/tm2114556-3_s1.htm | PENDING |
| 12 | Annovis Bio | 5 | Line 1057 — 10-K text: "expect FDA approval in 2024" + "established and/or proven" | https://www.sec.gov/Archives/edgar/data/1477845/000110465923040275/anvs-20221231x10k.htm | PENDING |
| 13 | AARD (target S-1) | 5 | Line 1173 — Orphan Drug Designation exact quote with page | — (target S-1 under review) | PENDING |
| 14 | AARD (target S-1) | 5 | Line 1179 — Breakthrough Therapy denial exact quote with page | — (target S-1 under review) | PENDING |
| 15 | AVEO Pharmaceuticals (escalation prompt) | 5 | Line 1251 — Specific complaint paragraphs for escalation slot | (same as #8) | PENDING |
| 16 | Tongue v. Sanofi (escalation prompt) | 5 | Line 1256 — Specific holdings for escalation slot | (same as #10) | PENDING |
| 17 | AARD (target S-1) | 3,4,5 | Line 1477 — All quoted S-1 passages referenced across Checks 3, 4, 5 | — (target S-1 under review) | PENDING |

## CHECKS 6, 7 (14 slots) — Source: checks_6_7.md

| # | Company | Check | Placeholder Location | Filing URL | Status |
|---|---------|-------|---------------------|-----------|--------|
| 18 | Taysha Gene Therapies | 6 | Line 38 — S-1 pipeline table/graphic: "Phase 1/2", "Pivotal", "IND-enabling" columns | https://www.sec.gov/Archives/edgar/data/1806310/000119312520247565/d938924ds1a.htm | PENDING |
| 19 | AARD (target S-1) | 6 | Line 156 — Pipeline graphic description: candidates, phases, visual design | — (target S-1 under review) | PENDING |
| 20 | Altamira Therapeutics | 7 | Line 353 — F-1 text: "safe and effective", "safe and well tolerated", "favorable safety profile" from pages 1, 11, 55-57, 79, 84, 88, 89 | https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001601936&type=F-1 | PENDING |
| 21 | Graybug Vision | 7 | Line 427 — S-1 text: "favorable safety and tolerability" from page 21 | https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001534133&type=S-1 | PENDING |
| 22 | Madrigal Pharmaceuticals | 7 | Line 464 — 10-K text: "safe and well tolerated" re Resmetirom from page 10 | https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001157601&type=10-K | PENDING |
| 23 | Scopus BioPharma | 7 | Line 525 — Form 1-A text: "acceptable safety profile" re MRI-1867 | https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001772028&type=1-A | PENDING |
| 24 | OS Therapies | 7 | Line 558 — S-1 text: "demonstrated that ADXS31-164 was well tolerated" | https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001795091&type=S-1 | PENDING |
| 25 | AARD (target S-1) | 7 | Line 729 — 7 cautionary "well-tolerated" instances with section/page and conditional framing | — (target S-1 under review) | PENDING |
| 26 | AARD (target S-1) | 7 | Line 740 — 9 standalone "well-tolerated" instances: exact quotes, sections, pages, nearby context | — (target S-1 under review) | PENDING |
| 27 | AARD (target S-1) | 7 | Line 764 — 2 affirmative "safe" uses: exact quotes with section/page | — (target S-1 under review) | PENDING |
| 28 | AARD (target S-1) | 7 | Line 776 — "effective" contextual analysis: market/competitor vs. drug-specific breakdown | — (target S-1 under review) | PENDING |
| 29 | AARD (target S-1) | 7 | Line 866 — Challenged S-1 text for each comparison pair (escalation prompt slot) | — (target S-1 under review) | PENDING |
| 30 | AARD (target S-1) | 7 | Line 1076 — Madrigal three-part test verification: SAE disclosure, count, basis for "well-tolerated" | — (target S-1 under review) | PENDING |
| 31 | AARD (target S-1) | 7 | Line 1127 — All 9 standalone "well-tolerated" + 2 "safe" instances with exact quotes | — (target S-1 under review) | PENDING |

## SUMMARY BY TYPE

### External S-1/Filing Text to Fetch (11 slots)
| Slot | Company | Source Doc |
|------|---------|-----------|
| 1 | Curanex Pharmaceuticals | checks_3_4_5.md |
| 2 | Virpax Pharmaceuticals | checks_3_4_5.md |
| 4 | Nuvalent | checks_3_4_5.md |
| 5 | Zenas BioPharma | checks_3_4_5.md |
| 6 | Khosla/Valo Health | checks_3_4_5.md |
| 11 | Aerovate Therapeutics | checks_3_4_5.md |
| 12 | Annovis Bio | checks_3_4_5.md |
| 18 | Taysha Gene Therapies | checks_6_7.md |
| 20 | Altamira Therapeutics | checks_6_7.md |
| 21 | Graybug Vision | checks_6_7.md |
| 22 | Madrigal Pharmaceuticals | checks_6_7.md |
| 23 | Scopus BioPharma | checks_6_7.md |
| 24 | OS Therapies | checks_6_7.md |

### Enforcement/Case Law to Fetch (4 slots)
| Slot | Source | Source Doc |
|------|--------|-----------|
| 8 | AVEO complaint (PDF) | checks_3_4_5.md |
| 9 | AVEO litigation release | checks_3_4_5.md |
| 10 | Tongue v. Sanofi holdings | checks_3_4_5.md |

### Escalation Prompt Duplicates (2 slots — same content as above)
| Slot | Duplicates | Source Doc |
|------|-----------|-----------|
| 15 | Same content as #8 (AVEO) | checks_3_4_5.md |
| 16 | Same content as #10 (Tongue v. Sanofi) | checks_3_4_5.md |

### AARD Target S-1 Text Needed (12 slots)
| Slot | What's Needed | Source Doc |
|------|--------------|-----------|
| 3 | Preclinical passages (Check 3) | checks_3_4_5.md |
| 7 | Comparative "differentiated" passage (Check 4) | checks_3_4_5.md |
| 13 | Orphan Drug Designation quote (Check 5) | checks_3_4_5.md |
| 14 | Breakthrough Therapy denial quote (Check 5) | checks_3_4_5.md |
| 17 | All Check 3/4/5 passages (aggregate) | checks_3_4_5.md |
| 19 | Pipeline graphic description (Check 6) | checks_6_7.md |
| 25 | 7 cautionary "well-tolerated" instances (Check 7) | checks_6_7.md |
| 26 | 9 standalone "well-tolerated" instances (Check 7) | checks_6_7.md |
| 27 | 2 affirmative "safe" instances (Check 7) | checks_6_7.md |
| 28 | "effective" contextual analysis (Check 7) | checks_6_7.md |
| 29 | Challenged S-1 text for escalation (Check 7) | checks_6_7.md |
| 30 | Madrigal three-part test verification (Check 7) | checks_6_7.md |
| 31 | All red flag instances aggregate (Check 7) | checks_6_7.md |
